Shenzhen Edge Medical (2675) H1 2026 earnings summary

Executive summary

• Revenue surged 113.8% year-over-year to RMB319.3 million, driven by rapid growth in surgical robot sales, especially overseas, with over 69% of revenue from international markets.

• Gross profit rose 118.0% to RMB204.6 million, with gross margin improving to 64.1% from 62.8% year-over-year, reflecting strong cost management and economies of scale.

• Net loss narrowed by 78.4% to RMB19.3 million, primarily due to increased sales volume, scale expansion, and disciplined cost management.

• Successful listing on the Hong Kong Stock Exchange in January 2026 enhanced capital strength and international presence.

• Product portfolio expanded with significant progress in AI integration and telesurgery capabilities.

Financial highlights

• Revenue: RMB319.3 million (up 113.8% year-over-year).

• Gross profit: RMB204.6 million (up 118.0% year-over-year); gross margin: 64.1%.

• Net loss: RMB19.3 million (down 78.4% year-over-year).

• R&D expenses: RMB53.8 million (down 44.2% year-over-year).

• Cash and cash equivalents: RMB1,260.1 million as of June 30, 2026.

• No interim dividend declared.

Outlook and guidance

• Plans to deepen domestic market presence and accelerate overseas commercialization.

• Continued investment in R&D, AI integration, digital surgery, and expansion of telesurgery ecosystem.

• Focus on operational efficiency, cost management, and sustainable profitability.

• Management confident in further international expansion and unlocking new growth potential through technological innovation.

• Product portfolio expansion includes multi-port, single-port, telesurgery, and bronchoscopy robots.